A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

NCT03641976 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy
Unresectable Metastatic Right-sided Colon Cancer, Stage IV

Interventions

DRUG: A-FOLFOXIRI
DRUG: Arm II (A-FOLFOX/A-FOLFIRI)

Sponsor

Yonsei University